Avalo Therapeutics (NASDAQ:AVTX) Receives “Buy” Rating from BTIG Research

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “buy” rating restated by BTIG Research in a note issued to investors on Tuesday,Benzinga reports. They currently have a $40.00 price objective on the stock. BTIG Research’s price objective points to a potential upside of 196.30% from the company’s current price.

A number of other equities research analysts have also recently commented on AVTX. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Avalo Therapeutics in a research report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Finally, Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Avalo Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $35.50.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $13.50 on Tuesday. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72. The firm has a market capitalization of $249.89 million, a price-to-earnings ratio of -2.52 and a beta of 0.84. The stock’s fifty day moving average is $15.65 and its two-hundred day moving average is $15.77.

Insider Activity

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the sale, the insider directly owned 3,622 shares of the company’s stock, valued at $58,495.30. This trade represents a 87.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.25% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AVTX. Geode Capital Management LLC boosted its position in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after acquiring an additional 2,648 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Avalo Therapeutics during the 2nd quarter worth $55,000. Velan Capital Investment Management LP lifted its stake in shares of Avalo Therapeutics by 38.4% during the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after purchasing an additional 43,000 shares during the period. Nantahala Capital Management LLC boosted its holdings in shares of Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after purchasing an additional 95,000 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Avalo Therapeutics by 7,066.8% in the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after purchasing an additional 400,898 shares during the period. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.